Skip to main content

Table 1 Correlations between ARHGAP9 expression and clinicopathological feathers in AML from TCGA cohort

From: The role of ARHGAP9: clinical implication and potential function in acute myeloid leukemia

Patient characteristics ARHGAP9 expression
Low (n = 76) High (n = 75) p
Sex, male/female 38/38 45/30 0.217
Median age, years (range) 53.5 (21–77) 60 (21–88) 0.091
Median BM blasts, % (range) 75 (30–100) 69 (30–99) 0.071
Median WBC, × 109/L (range) 13.35 (0.4–137.2) 27.6 (0.6–223.8) 0.194
Median PB blasts, % (range) 40 (0–97) 39 (0–96) 0.322
FAB classifications
 M0 6 9 0.399
 M1 12 24 0.019
 M2 14 23 0.067
 M3 14 0 0
 M4 16 5 0.011
 M5 10 1 0.005
 M6 1 0 1
 M7 1 0 1
 NA 1 0 1
Cytogenetics
 Normal 24 37 0.026
 t(8;21) 3 4 0.719
 t(15;17) 14 0  < 0.001
 inv.(16) 7 3 0.327
 + 8 5 3 1
 11q23 7 1 0.063
 -7/del(7) 2 4 0.442
 Complex 5 13 0.041
 Others 8 8 0.978
 No data 1 2 1
Risk level
 Good 24 7 0.001
 Intermediate 34 45 0.060
 Poor 17 21 0.453
 NA 1 2 1
  1. n number of patients, FAB French–American–British subtypes, BM-blast, bone marrow blast, PB-blast peripheral blood blast, WBC white blood cell